PD-1 Protein, Human (HEK293, hFc)
Based on 1 publication(s) in Google Scholar
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1, Human (HEK293, hFc) is the recombinant human-derived PD-1 protein, expressed by HEK293, with Tag Free labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- Help & FAQs
Biological Activity
Description
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1, Human (HEK293, hFc) is the recombinant human-derived PD-1 protein, expressed by HEK293, with Tag Free labeled tag.
Background
PD-1 protein functions as an inhibitory receptor on antigen-activated T-cells, playing a crucial role in the induction and maintenance of immune tolerance to self. Upon binding to its ligands CD274/PDCD1L1 and CD273/PDCD1LG2, PD-1 delivers inhibitory signals and associates with CD3-TCR in the immunological synapse, directly impeding T-cell activation. This inhibitory action is further executed through the recruitment of PTPN11/SHP-2, leading to the dephosphorylation of key TCR proximal signaling molecules. Exploited by tumors to attenuate anti-tumor immunity, PD-1's interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. Blockage of the PD-1-mediated pathway has shown promise in reversing the exhausted T-cell phenotype and normalizing the anti-tumor response, providing a rationale for cancer immunotherapy.
Verified Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human PD-1 at 2 μg/mL (100 μL/well) can bind Human PD-L1 (HY-P7398). The ED50 for this effect is < 50 ng/mL.
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
-
Bioactivity - ELISA
Bioactivity - ELISA
Publications (1)
-
Journal Impact Factor
-
Most Recent
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-hFc
-
Accession
Q15116 (L25-Q167)
-
Gene ID5133
-
Molecular Construction
-
N-term
-
PD-1 (L25-Q167)
Accession # Q15116 -
hFc
-
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
PDCD1; Systemic Lupus Erythematosus Susceptibility 2; Prev. SLEB2; HPD-1; PD1; Programmed Cell Death 1 Protein; Programmed Cell Death Protein 1; CD279 Antigen; CD279; ADMIO4; HSLE1; AIMTBS; PD-1; HPD-L; Programmed Cell Death 1; Protein PD-1
-
Predicted Molecular Mass
42 kDa
-
Molecular Weight
Approximately 55-70 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.;≥ 90%, as determined by HPLC.
Product Properties
Lyophilized powder
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 8% trehalose.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
